“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s358. Accessed October 6, 2025. https://skin.dermsquared.com/skin/article/view/2653.